Estrenue

Estrenue is an Australian biotechnology company focused on developing targeted topical hormone therapies for dermatological conditions and skin aging. The company's lead candidate, EST-001, utilizes a proprietary Elongated Microparticle (EMP) delivery system to deliver estradiol directly to the dermal layer of the skin. This localized approach aims to treat conditions like rosacea and reverse signs of skin aging while avoiding systemic estrogen exposure and its associated risks, such as breast cancer and cardiovascular issues. Estrenue is led by a team of experts in estrogen biology and dermatology, including founders from HAVAH Therapeutics. The company's technology represents a significant breakthrough in topical drug delivery, combining safety and efficacy for aging skin treatments.